This relates to an amorphous form of daclatasvir and its salts and process for preparation thereof. In particular, it relates to an amorphous form of daclatasvir and daclatasvir dihydrochloride. It also relates to pharmaceutical compositions comprising an amorphous form of daclatasvir or daclatasvir dihydrochloride for oral administration for treatment of Hepatitis C virus (HCV).